Latest Biotechnology, Pharmaceutical and Healthcare News from Zyme Communications

03:34 EST 19th January 2019 | BioPortfolio

Here are the most relevant search results for "Zyme Communications" found in our extensive news archives from over 250 global news sources.

More Information about Zyme Communications on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zyme Communications for you to read. Along with our medical data and news we also list Zyme Communications Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zyme Communications Companies for you to search.

Showing News Articles 1–25 of 401 from Zyme Communications

Tuesday 15th January 2019

Phico Therapeutics appoints Financial Director and two Non-Executives.

Senior management team and Board strengthened with Andrew Armour joining as Financial Director, and Professor Mark Wilcox and David Beadle as Non-Executive Directors CAMBRIDGE, UK, 15 January 2019 – Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing a novel platform technology as the basis of a new generation of antibiotics to overcome antibacterial resis...

Sphere Fluidics collaborates with Peak Analysis and Automation to increase throughput in antibody discovery and cell line development

  PAA’s S-LAB micro-plate handling capability will be integrated with Sphere Fluidics’ Cyto-Mine Single Cell Analysis System  Cambridge and Farnborough, UK, 15 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the d...

Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation

Appointment will drive scientific and technical innovation to streamline process workflows and advance ATMP service offering Keele, UK, 15 January 2019: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, today announced the appointment of Dr Darrell Sleep as Director of Innovation. The appointment is part of on-going strategic expansion activities currently un...

Monday 14th January 2019

Evonetix appoints Stephanie Brooking as Head of Product Management

Stephanie Brooking to support Evonetix in developing its strategy for market entry CAMBRIDGE, UK, 14 January 2019 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, today announced it has appointed Stephanie Brooking as Head of Product Management. Evonetix aims to utilise its innovative s...

Thursday 10th January 2019

Bio-Rad Publishes New Findings on Generation and Characterization of Drug-Target Complex-Specific Antibodies

Published in the Peer-Reviewed Journal mAbs, the Paper Introduces Complex-Specific Antibodies for Pharmacokinetic Analysis of Biotherapeutics HERCULES, Calif.–10 January, 2019–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has published new findings on the generation and characterization of drug-target co...

Wednesday 9th January 2019

Expedeon AG licenses Lightning-Link Rapid Biotinylation technology to Cell Guidance Systems in supply agreement

  License allows Cell Guidance Systems to use Lightning-Link® in manufacture of TRIFic™ exome detection immunoassay kits Expedeon becomes preferred immunoreagent supplier to Cell Guidance Systems   Heidelberg, Germany and Cambridge, UK, 09 January 2019 – Expedeon AG (

Thursday 3rd January 2019

Clinical Trial Launches to Develop Breath Test for Multiple Cancers.

Cancer Research UK recruits first patients in trial to improve the early detection and diagnosis of different cancer types Study will use Owlstone Medical’s Breath Biopsy platform to identify breath biomarkers to detect and differentiate early-stage disease Study will recruit 1,500 patients at Addenbrooke’s Hospital, Cambridge Cambridge, UK, January 3rd 2019: Owlston...

Wednesday 2nd January 2019

Leading cell culture media company changes name to “FUJIFILM Irvine Scientific, Inc.”

FUJIFILM Irvine Scientific, Inc. (President: Yutaka Yamaguchi, FISI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno), and a leading company in cell culture media, today announced that on January 1, 2019 in the United States, the company changed its name from Irvine Scientific Sales Company, Inc. The new company name combines the “FUJIFILM” brand, which is reco...

Thursday 20th December 2018

Evonetix establishes scientific advisory board

Prof David Klenerman and Prof Andrew Briggs appointed as scientific advisors CAMBRIDGE, UK, 20 December 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, today announces the formation of its scientific advisory board (SAB). Evonetix has appointed Prof David Klenerman FMedSci FRS and...

Tuesday 18th December 2018

Horizon Discovery Group plc enters an exclusive partnership with C4X Discovery Holdings plc to validate targets and develop next-generation oncology drugs

Cambridge, UK, 17 December 2018: Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD) ("C4XD"), a pioneering drug discovery company. The partnership aims to validate the novel synthetic ...

Wednesday 12th December 2018

Avacta appoints Dr Jose Saro as Chief Medical Officer

Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s ...

Tuesday 11th December 2018

IONTAS founder and phage display pioneer attends Nobel Prize Award Ceremony.

Dr John McCafferty celebrates success of phage display technology with Nobel Prize in Chemistry Laureates Cambridge, UK, 11 December 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribut...

Monday 10th December 2018

Avacta and LG Chem Life Sciences agree multi-target Affimer therapeutics development alliance

Cambridge, UK and Seoul, South Korea, 10 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and LG Chem Life Sciences, the life sciences division of the South Korean LG Group, today announced a multi-target collaboration and development agreement. The agreement provides LG Chem with the exclusive rights to develop and commercialize, on a w...

Tuesday 4th December 2018

Concept Life Sciences forms Scientific Advisory Board.

      SAB will help to guide Concept Life Sciences’ scientific strategy for its drug discovery and development services business SAB Members are leading experts in a diverse range of therapeutic areas   

Monday 26th November 2018

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

Keele, UK, Port Washington, USA, and London, UK, 26 November 2018: Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency. Co-winners, Pall Corporation, a global leader in filtration, separat...

Wednesday 7th November 2018

Concept Life Sciences extends GLP accreditation to support regulatory studies

MHRA confirms GLP extension at Dundee and Bradford sites Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries Manchester and Dundee, UK, 07 November 2018: Concept Life Sciences (“Concept”), the integrated drug discovery and development and analytical services company, today announced the expansion...

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products Heidelberg, Germany and Cambridge, UK, 07 November 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provi...

Tuesday 6th November 2018

Optibrium and University of Nottingham Collaborate on Innovative Teaching Programme

Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software CAMBRIDGE and NOTTINGHAM, UK, 5th November 2018 – Optibrium™, a developer of software for drug discovery, today announced it had entered into a collaboration with the University of Nottingham, a pioneering research institution...

Friday 2nd November 2018

Diamond Pharma Services wins both Futures and Support categories at TOPRA Awards.

Double-win recognises Diamond’s role supporting Kite Pharma Inc in the development of its breakthrough CAR-T cell cancer therapy Harlow, Essex, UK, 02 November 2018 – Diamond Pharma Services Ltd (“Diamond”), a leading technical services and regulatory affairs consulting group, providing expert support and advice to pharmaceutical and biotechnology companies, has rece...

Thursday 1st November 2018

Horizon Discovery partners with Biocartis to provide reference standards for recently launched Idylla™ microsatellite instability assay

First commercially available reference standard for microsatellite instability (MSI) testing Horizon Discovery’s reference material covers seven new MSI markers tested for on the Idylla™ platform MSI is a form of genetic instability that is predominantly found in colorectal, gastric and endometrial cancer and serves as a prognostic, diagnostic and predictive marker in t...

Tuesday 30th October 2018

Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project

£100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields Keele and Leeds, UK, 30 October 2018: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the University of Leeds have been awarded £100,000 to investigate the effects of hydrodynamic force on the structure and bi...

TTP Ventus introduces the XP Series of micropumps

 Award-winning Disc Pump range expanded to address a broader range of applications New micropump series offers improved performance, efficiency, and wider operating temperature range The XP Series will be on display at MEDICA 2018 in Düsseldorf, Germany  Cambridge, UK, 30 October 2018: TTP Ventus, manufacturer of the Disc Pump range of multi-award-winning micropum...

Wednesday 24th October 2018

Aigenpulse expands into new facilities in Oxford, UK and Boston, US

New premises at Milton Park, Oxfordshire, UK and in Boston, MA support rapid expansion of company Oxford, UK, 24 October 2018: Aigenpulse Ltd., (Aigenpulse), a company at the forefront of employing data technologies and advanced machine learning to accelerate drug discovery, today announced it has moved into larger premises at Milton Park, Oxfordshire, UK and opened offices at the CIC in Bo...

Wednesday 17th October 2018

Pioneering Surgical Guidance System from Endomag Wins Institute of Physics’ Business Innovation Award

Cambridge, UK, 17 October 2018 : Endomag, the surgical guidance company, has won a prestigious British Business Innovation Award from the Institute of Physics (IOP), presented at the Houses of Parliament in London. The IOP is the professional and learned society for physics in the UK and Ireland, encouraging innovation, growth and productivity in business. This award recognises Endomag&r...

Tuesday 16th October 2018

Arcis Biotechnology and Teleflex sign license agreement

Agreement gives Teleflex access to Arcis’ nucleic acid sample preparation technology Daresbury, UK, 16 October 2018: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has signed a technology access agreement with Teleflex Incorporated, a New York Stock Exchange listed company (NYSE: TFX). Teleflex will harness Arcis&rs...

Quick Search


News Quicklinks